Alkermes begins supportive clinical study of ALKS 3831 to treat schizophrenia

Irish-based biopharmaceutical company Alkermes has begun its supportive clinical study of ALKS 3831 for the treatment of schizophrenia.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news